; (F) allowing virtual or telemedicine visits; (G) use of wearable technology to record key health parameters; and (H) use of alternate labs or imaging centers, which may be closer to the residence of the patients participating in the trial; and (5) the sponsor’s education and training requirements for researchers and other individuals conducting or supporting the clinical trial with respect to diversity and health inequities in, and the development of, curricula for healthcare professionals on how to participate in clinical trials as an investigator and how they can enroll patients in trials, which may include consultation with, and the review of materials made available by, such committees, task forces, working groups, and other entities the Director determines are appropriate, including the following: (A) The Equity Committee of the National Institutes of Health. (B) The National Advisory Council on Minority Health and Health Disparities. (C) The Advisory Committee on Research on Women's Health. (D) The Tribal Health Research Coordinating Committee of the National Institutes of Health. (b) Terms (1) In general As a condition on the approval of a protocol to conduct a clinical trial by the National Institutes of Health, as described in subsection (a), the sponsor of the clinical trial shall agree to terms requiring that— (A) the aggregate demographic information of trial participants be shared on an annual basis with the Secretary while participant recruitment and data collection in such trial is ongoing, and that such information is provided with respect to— (i) underrepresented populations, including populations grouped by race, ethnicity, age, and sex; and (ii) such populations that reflect the prevalence of the disease or condition that is the subject of the clinical trial involved (as available and as appropriate to the scientific objective for the study, as determined by the Director of the National Institutes of Health)